These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34661185)

  • 1. Shaping EU medicines regulation in the post COVID-19 era.
    Cavaleri M; Sweeney F; Gonzalez-Quevedo R; Carr M
    Lancet Reg Health Eur; 2021 Oct; 9():100192. PubMed ID: 34661185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stakeholders' Understanding of European Medicine Agency's COVID-19 Vaccine Information Materials in EU and Regional Contexts.
    Castro I; Van Tricht M; Bonaccorso N; Sciortino M; Garcia Burgos J; Costantino C; Gonzalez-Quevedo R
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37897018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Shivji R; Conocchia R; Korakianiti E; Jekerle V
    Vaccine; 2022 Sep; 40(38):5539-5541. PubMed ID: 35779964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public information on shortages in the EU/EEA: improvements made between 2018 and 2020.
    Abed I; Garcia Burgos J; Knudsen Y
    Eur J Hosp Pharm; 2024 Jun; 31(4):344-347. PubMed ID: 36754622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
    Kwon HY; Kim H; Godman B
    Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?
    Klein K; Stolk P; Tellner P; Acha V; Montagne S; Stöckert I
    Ther Innov Regul Sci; 2022 Mar; 56(2):366-377. PubMed ID: 35129827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the European Medicines Agency in multi-stakeholder regulatory science research projects: experiences of staff members and project coordinators.
    Saesen R; Machado M; Crifo B; Liu L; de Vries C; Herold R; Llinares Garcia J; Huys I
    Front Med (Lausanne); 2023; 10():1181702. PubMed ID: 37324145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Risk Assessment in the European Food Safety Authority: Lessons From the European Medicines Agency.
    Chatzopoulou S; Eriksson NL; Eriksson D
    Front Plant Sci; 2020; 11():349. PubMed ID: 32318080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of real-time global media monitoring and 'derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines.
    Bahri P; Fogd J; Morales D; Kurz X;
    BMC Med; 2017 May; 15(1):91. PubMed ID: 28464900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins.
    Althunian TA; de Boer A; Mantel-Teeuwisse AK; Groenwold RHH; Gispen-de Wied CC; Leufkens HGM; Klungel OH
    Clin Ther; 2020 Aug; 42(8):1588-1594. PubMed ID: 32782135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
    Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMA's mishandling of an investigation into suspected serious neurological harms of HPV vaccines.
    Gøtzsche PC; Jørgensen KJ
    BMJ Evid Based Med; 2022 Feb; 27(1):7-10. PubMed ID: 33514652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
    Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
    Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
    [No Abstract]   [Full Text] [Related]  

  • 19. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.